AcelRx Pharmaceuticals

AcelRx appoints Adrian Adams to board

Tuesday, February 12, 2013 08:00 AM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on acute and breakthrough pain, has appointed Adrian Adams, CEO and president of Auxilium Pharmaceuticals, to its board of directors as chairman of the board.  

More... »


Foresite closes $100M growth capital fund for late-stage healthcare companies

Friday, February 1, 2013 02:12 PM

Foresite Capital Management, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, has closed its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners' experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.

More... »


AcelRx doses first patients in ARX-04 phase II study in pain

Wednesday, November 7, 2012 03:09 PM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of acute and breakthrough pain, has dosed the first subjects in a phase II, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate. 

More... »

AcelRx names Edwards to board of directors

Wednesday, September 28, 2011 11:55 AM

AcelRx Pharmaceuticals has named Mark G. Edwards to its board of directors. Edwards will also serve as the chairman of the audit committee.

More... »

AcelRx gets $20M loan

Tuesday, July 5, 2011 12:00 PM

AcelRx Pharmaceuticals has secured a $20 million loan from Hercules Technology Growth Capital, according to FierceBiotech.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs